NEWSVERUM / Data desk

Disease and condition

IPTC Media Topics 2026-Q2 · IPTC · CC BY 4.0

Article subject labels can be suggestions and are not editorial confirmation.

Related subjects

Health

PAQ Therapeutics presents first Phase 1 clinical data for KRAS G12D degrader PT0253 at ENA 2026

PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.

PAQ Therapeutics, First Clinical Data for PT0253 KRAS G12D Degrader at ENA 20264 min read Data included
Health

Correction: Gavi's 4 November malaria-vaccine milestone was not verified

UNICEF reported more than 74 million doses procured and delivered by 22 October. That is a delivery count, distinct from completed vaccination courses or a 2030 target for children.

Unverified historical source reference (former attribution: Gavi Vaccine Alliance Operational Monitoring)3 min read Data included